Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the oncology-focused platform company’s decision to file for bankruptcy. Notable's ...
Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...
INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal ...
Hosted on MSN7mon
FDA approves Boehringer’s SPEVIGO for psoriasis treatmentThe US Food and Drug Administration (FDA) has granted approval for Boehringer Ingelheim's SPEVIGO injection to treat generalised pustular psoriasis (GPP). The treatment is indicated for use in adult ...
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
The heritage of Boehringer Ingelheim in developing medicines for respiratory diseases spans almost 100 years. Within the respiratory disease area, innovative treatments for chronic obstructive ...
Boehringer Ingelheim is supporting this transformation by partnering with groups working across psychiatric R&D, from small molecules to digital therapeutics. Recognizing the potential to improve ...
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...
Boehringer Ingelheim and Takeda are the only two pharmaceutical groups to be named among the 15 Global Top Employers for 2023, an award dedicated to companies that enrich the workplace environment.
Der Börsenhype rund um die sogenannten Fettweg-Spritzen ist ungebrochen. Jetzt rückt ein neuer Kandidat in der Fokus der Investoren. Genau wie beim Börsenstar Novo Nordisk handelt es sich um ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback